BPC-157 Dosing Guide: Protocols, Timing, and What the Research Shows

Getting BPC-157 dosing right matters more than most people realize. Too little and you may not see results. Too much and you’re wasting peptide without additional benefit — at least based on what the animal data suggests. The problem is that no human clinical trials have established an official dose, so every protocol you’ll find is extrapolated from rat and dog studies.

This guide covers how researchers arrived at the commonly used doses, what the pharmacokinetics data actually shows, and how practitioners typically structure BPC-157 protocols. Whether you’re considering the oral or injectable route, the dosing logic is grounded in the same animal research — but the numbers differ based on delivery method.

Key Takeaways

The standard research dose in animals is 10 mcg/kg body weight, used across hundreds of rat studies on tendons, gut tissue, muscle, and nerves [1]
Human-equivalent doses typically range from 250-500 mcg per day, based on allometric scaling from animal data [2]
Cycle length in most protocols runs 4-6 weeks, though some practitioners extend to 8-12 weeks for chronic conditions
No human pharmacokinetics or dose-finding studies have been published — all dosing guidance is extrapolated, not clinically validated

Where the Dosing Data Comes From
Standard Doses: What Most Protocols Use
Injectable Dosing Protocols
Oral Dosing Protocols
Dose Calculation: From Rat Data to Human Use
Cycle Length and Timing
Stacking Doses: BPC-157 with Other Peptides
Reconstitution Math
Side Effects and Dose-Related Safety
FAQ
Sources

Where the Dosing Data Comes From

Nearly every BPC-157 study uses rats or mice. The standard dose across this literature is 10 mcg/kg of body weight, administered either intraperitoneally (into the abdominal cavity) or orally in drinking water [1]. Some studies use 10 ng/kg (a thousand times lower) as a comparison dose, and a handful go up to 50 mcg/kg.

Professor Predrag Sikiric and colleagues at the University of Zagreb have published the majority of BPC-157 research since the early 1990s. Their work established the 10 mcg/kg dose as the standard, showing consistent effects across gut, tendon, muscle, nerve, and vascular tissue at this level [3].

A 2022 pharmacokinetics study by Xu et al. — one of the few to measure BPC-157 absorption and distribution — estimated a clinical dose of 200 mcg/person/day based on body surface area conversion from the rat dose of 20 mcg/kg [2]. This is on the lower end of what most practitioners prescribe.

The honest reality: there’s no phase I dose-escalation trial, no maximum tolerated dose study, and no dose-response curve in humans. Every number you see is an educated extrapolation.

Standard Doses: What Most Protocols Use

Based on allometric scaling and clinical practice patterns, BPC-157 doses generally fall into three tiers:

Low dose: 200-250 mcg/day

Based directly on the Xu et al. pharmacokinetics estimate [2]
Often used for maintenance, mild injuries, or general gut support
Single daily administration

Standard dose: 500 mcg/day

The most commonly reported dose across peptide clinics
Usually split into 250 mcg twice daily or taken as a single 500 mcg dose
Used for moderate injuries, tendon issues, and recovery support [4]

Higher dose: 750-1,000 mcg/day

Used by some practitioners for severe or chronic injuries
Typically split into two daily administrations
Less research support — the jump from 500 mcg to 1,000 mcg is practitioner-driven, not data-driven

Body weight plays a role in dose selection. A 200 lb person at 10 mcg/kg would theoretically need around 900 mcg/day — but this straight conversion doesn’t account for differences in metabolism between rats and humans. Allometric scaling (which adjusts for body surface area) produces the lower figures most practitioners use [2].

Injectable Dosing Protocols

For subcutaneous injection, typical protocols look like this:

Acute injury protocol:

250-500 mcg injected subcutaneously, twice daily
Inject near the injury site when practical
Duration: 4-6 weeks
Reconstitute with bacteriostatic water before first use

Maintenance/recovery protocol:

250 mcg once daily
Subcutaneous injection in abdominal fat pad
Duration: 4-8 weeks

Timing: Most practitioners recommend injecting on an empty stomach or at least 30 minutes before eating. BPC-157 is a peptide, and food intake can affect absorption kinetics — though this hasn’t been formally studied in humans.

Injection site matters. For a knee tendon issue, subcutaneous injection around the knee is preferred over injection in the abdomen. The logic is local tissue concentration, though no controlled studies have compared injection proximity to outcomes in humans.

Insulin syringes (29-31 gauge, 0.5 mL) are standard for subcutaneous BPC-157 injection. The small gauge minimizes discomfort and tissue damage.

Oral Dosing Protocols

Oral BPC-157 is typically dosed higher than injectable because systemic bioavailability is lower through the gut [2]. However, for gut-specific conditions, lower oral doses may be sufficient since the peptide acts locally on the GI lining.

Gut healing protocol:

250-500 mcg taken orally, once or twice daily
Empty stomach preferred (20-30 minutes before food)
Duration: 4-8 weeks

Systemic recovery (oral):

500-750 mcg daily
Some practitioners go up to 1,000 mcg/day for non-gut targets
The higher dose attempts to compensate for lower systemic bioavailability

In Sikiric’s rat studies, oral BPC-157 was delivered in drinking water at concentrations of 0.16 mcg/mL, with rats consuming approximately 12 mL/day [5]. The total daily oral dose in these studies was in the low microgram range — far lower than what’s commonly prescribed to humans. This discrepancy reflects the challenge of scaling oral peptide doses across species.

Dose Calculation: From Rat Data to Human Use

For those who want to understand the math behind human dosing:

Standard rat dose: 10 mcg/kg body weight

Direct weight conversion for an 80 kg human: 10 mcg/kg × 80 kg = 800 mcg/day

Allometric scaling (body surface area method): Rat-to-human conversion factor is approximately 0.162. So: 10 mcg/kg × 0.162 = ~1.6 mcg/kg for humans. For an 80 kg person: ~130 mcg/day.

Xu et al. estimate: 200 mcg/person/day (using 20 mcg/kg rat dose with body surface area conversion) [2].

The commonly used 250-500 mcg/day range sits between the allometric minimum and the direct weight conversion maximum. Most practitioners land in this middle ground, reasoning that the allometric conversion may underestimate while the direct conversion likely overestimates.

None of these calculations have been validated by human dose-response studies. They’re the best available estimates from animal pharmacokinetics data — nothing more.

Cycle Length and Timing

Typical cycle: 4-6 weeks. This comes from the duration of most animal studies, which run 14-28 days in rats [1][5]. Adjusted for human recovery timelines and clinical experience, 4-6 weeks is the standard first protocol.

Extended cycles: 8-12 weeks. Some practitioners use longer protocols for chronic conditions — persistent tendinopathy, long-standing gut issues, or post-surgical recovery. The safety data from animal studies (which show no toxicity at standard doses over extended periods) provides some reassurance, but human long-term data doesn’t exist [6].

Time of day: No studies have examined whether morning vs evening dosing affects outcomes. Most protocols default to morning administration on an empty stomach, simply because fasting may improve peptide absorption.

Cycling off: Many practitioners recommend taking 2-4 weeks off between cycles. The rationale is to avoid receptor desensitization, though there’s no published evidence that BPC-157 causes desensitization at standard doses. This is borrowed from general peptide therapy practice rather than BPC-157-specific data.

Stacking Doses: BPC-157 with Other Peptides

BPC-157 is frequently combined with other recovery peptides. The most popular stack is the Wolverine stack — BPC-157 + TB-500.

BPC-157 + TB-500 (Wolverine Stack):

BPC-157: 250-500 mcg/day
TB-500: 750-2,000 mcg, 2-3x per week (loading), then weekly (maintenance)
The two peptides work through different mechanisms — BPC-157 via growth factor upregulation and angiogenesis, TB-500 via actin binding and cell migration [7]

BPC-157 + GHK-Cu:

Sometimes combined for wound healing and tissue remodeling
GHK-Cu has its own dosing protocol and can be administered topically, adding a non-injection option

When stacking, each peptide maintains its individual dose. There’s no published research on dose adjustment when combining BPC-157 with other peptides — practitioners use the standard dose for each compound independently.

Be aware that stacking increases both cost and potential side effects. More isn’t automatically better, and the interaction between multiple peptides hasn’t been studied in controlled settings.

Reconstitution Math

If you’re using injectable BPC-157, you’ll receive it as a lyophilized (freeze-dried) powder that needs to be reconstituted with bacteriostatic water.

Common setup: 5 mg vial + 2 mL bacteriostatic water

Concentration: 2.5 mg/mL (2,500 mcg/mL)
For a 250 mcg dose: draw 0.1 mL (10 units on an insulin syringe)
For a 500 mcg dose: draw 0.2 mL (20 units)
Vial provides: 10 doses at 500 mcg, or 20 doses at 250 mcg

Alternative: 5 mg vial + 5 mL bacteriostatic water

Concentration: 1 mg/mL (1,000 mcg/mL)
For a 250 mcg dose: draw 0.25 mL (25 units)
For a 500 mcg dose: draw 0.5 mL (50 units)
Easier math, but larger injection volume

Storage after reconstitution: Refrigerate at 2-8°C. Use within 28 days. Don’t freeze reconstituted peptide — it degrades the solution.

Double-check your math before every injection. A decimal error with a concentrated solution means a 10x dosing mistake.

BPC-157 has not reached a lethal dose in animal studies — researchers have not been able to establish an LD50, which suggests a wide safety margin [6]. At the standard 10 mcg/kg dose, animal studies report no significant adverse effects.

Reported side effects in humans (from clinical practice, not trials) are generally mild:

Nausea: More common at higher oral doses, especially without food
Injection site irritation: Redness or mild swelling, usually resolves in hours
Dizziness or lightheadedness: Occasional, typically with first few doses
Headache: Infrequent

The theoretical concern with higher doses relates to BPC-157’s pro-angiogenic properties. By promoting blood vessel formation, there’s a hypothetical risk for people with active cancers or conditions where new blood vessel growth is problematic [8]. No studies have confirmed this risk, but it’s a commonly cited precaution.

Starting at the low end of the dosing range (250 mcg/day) and increasing if needed is standard practice. There’s no evidence that starting high provides faster results, and lower initial doses help identify any individual sensitivity.

FAQ

What is the best BPC-157 dose for tendon injuries?▼

Most practitioners recommend 250-500 mcg per day via subcutaneous injection near the injured tendon. This is based on allometric scaling from the 10 mcg/kg dose used in rat tendon studies [1]. A 4-6 week cycle is typical for acute tendon issues.

Should I take BPC-157 once or twice a day?▼

Both approaches are used. Some practitioners prefer 500 mcg once daily for convenience. Others split it into 250 mcg twice daily (morning and evening) for more consistent peptide levels. No study has compared these schedules, so it’s largely personal preference and practitioner guidance.

How long should a BPC-157 cycle last?▼

Standard protocols run 4-6 weeks. For chronic conditions, some practitioners extend to 8-12 weeks with monitoring. Most recommend a 2-4 week break between cycles, though the evidence for mandatory cycling is limited.

Can I take too much BPC-157?▼

Animal studies show no lethal dose and no significant toxicity at standard doses [6]. However, doses above 1,000 mcg/day are outside the range supported by even generous interpretations of the animal data. More peptide doesn’t necessarily mean more healing — there may be a ceiling effect, though this hasn’t been formally studied.

Do I need to take BPC-157 on an empty stomach?▼

Most protocols recommend it. Peptides can interact with food proteins during digestion, potentially reducing absorption. Taking BPC-157 20-30 minutes before eating is standard practice for both oral and injectable forms, though no human study has tested the difference between fasted and fed administration.

Sources

Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response.” Gut. 2020;69(3):564-573. PMC7096228
Xu C, et al. “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs.” Front Pharmacol. 2022;13:1026182. DOI
Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMC5333585
Gwyer D, et al. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell Tissue Res. 2019;377(2):153-159. DOI
Krivic A, et al. “Achieving the therapeutic effect of BPC 157 in tendons.” Biomedicines. 2021;9(11):1547. DOI
Korkmaz M, et al. “Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review.” Am J Sports Med. 2025. PMC12313605
Sikiric P, et al. “Pentadecapeptide BPC 157 and the central nervous system.” Neural Regen Res. 2022;17(3):482-487. PMC8504390
Vukojevic J, et al. “Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review.” Pharmaceuticals. 2025;18(2):185. DOI